Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 23, 2014 - Issue 6
Submit an article Journal homepage
792
Views
24
CrossRef citations to date
0
Altmetric
Reviews

Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer

Morena FasanoSecond University of Naples, Medical Oncology, Department of Experimental and Internal Medicine “F. Magrassi e A. Lanzara” , Via S. Pansini 5, 80131 Napoli, Italia+39 081 5666745; +39 081 5666732; [email protected]
,
Carminia Maria Della CorteSecond University of Naples, Medical Oncology, Department of Experimental and Internal Medicine “F. Magrassi e A. Lanzara” , Via S. Pansini 5, 80131 Napoli, Italia+39 081 5666745; +39 081 5666732; [email protected]
,
Raffaele CalifanoCancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, M20 4BX, UK;University Hospital of South Manchester, Department of Medical Oncology, Manchester, M23 9LT, UK
,
Annalisa CapuanoSecond University of Naples, Regional Centre of Pharmacovigilance and Pharmacoepidemiology. Department of Experimental Medicine “L. Donatelli”, Via De Crecchio, 7, 80138 Naples, Italy
,
Teresa TroianiSecond University of Naples, Medical Oncology, Department of Experimental and Internal Medicine “F. Magrassi e A. Lanzara” , Via S. Pansini 5, 80131 Napoli, Italia+39 081 5666745; +39 081 5666732; [email protected]
,
Erika MartinelliSecond University of Naples, Medical Oncology, Department of Experimental and Internal Medicine “F. Magrassi e A. Lanzara” , Via S. Pansini 5, 80131 Napoli, Italia+39 081 5666745; +39 081 5666732; [email protected]
,
Fortunato CiardielloSecond University of Naples, Medical Oncology, Department of Experimental and Internal Medicine “F. Magrassi e A. Lanzara” , Via S. Pansini 5, 80131 Napoli, Italia+39 081 5666745; +39 081 5666732; [email protected]
&
Floriana MorgilloSecond University of Naples, Medical Oncology, Department of Experimental and Internal Medicine “F. Magrassi e A. Lanzara” , Via S. Pansini 5, 80131 Napoli, Italia+39 081 5666745; +39 081 5666732; [email protected]
 show all
Pages 809-821 | Published online: 28 Mar 2014

Citations (24)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Amanda T.S. Albanaz, Carlos H.M. Rodrigues, Douglas E.V. Pires & David B. Ascher. (2017) Combating mutations in genetic disease and drug resistance: understanding molecular mechanisms to guide drug design. Expert Opinion on Drug Discovery 12:6, pages 553-563.
Read now

Articles from other publishers (23)

Qian Zhong, Xina Xiao, Yijie Qiu, Zhiqiang Xu, Chunyu Chen, Baochen Chong, Xinjun Zhao, Shan Hai, Shuangqing Li, Zhenmei An & Lunzhi Dai. (2023) Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications. MedComm 4:3.
Crossref
Camilla Pecoraro, Daniela Carbone, Stella Maria Cascioferro, Barbara Parrino & Patrizia Diana. (2023) Multi or Single-Kinase Inhibitors to Counteract Drug Resistance in Cancer: What is New?. Current Medicinal Chemistry 30:7, pages 776-782.
Crossref
Rajashri R. Naik & Ashok K. Shakya. (2023) Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update. Frontiers in Pharmacology 13.
Crossref
Biyu Zhang, Genyan Liu, Xin Wang & Xuelei Hu. (2022) Identification of Molecular Targets and Potential Mechanisms of Yinchen Wuling San Against Head and Neck Squamous Cell Carcinoma by Network Pharmacology and Molecular Docking. Frontiers in Genetics 13.
Crossref
Su-Jin Baek, Haeseung Lee, Sang-Min Park, Musun Park, Jin-Mu Yi, No Soo Kim, Aeyung Kim & Seongwon Cha. (2022) Identification of a novel anticancer mechanism of Paeoniae Radix extracts based on systematic transcriptome analysis. Biomedicine & Pharmacotherapy 148, pages 112748.
Crossref
Sabeeha Ali, Manzar Alam & Md. Imtaiyaz Hassan. 2022. Protein Kinase Inhibitors. Protein Kinase Inhibitors 1 22 .
Meenakshisundaram Balasubramaniam, Naga Rajiv Lakkaniga, Ayed A Dera, Majed Al Fayi, Mohammed Abohashrh, Irfan Ahmad, Harish C. Chandramoorthy, Ganesan Nalini & Prasanna Rajagopalan. (2020) FCX‐146, a potent allosteric inhibitor of Akt kinase in cancer cells: Lead optimization of the second‐generation arylidene indanone scaffold. Biotechnology and Applied Biochemistry 68:1, pages 82-91.
Crossref
Morena Fasano, Carminia Maria Della Corte, Giuseppe Viscardi, Raimondo Di Liello, Fernando Paragliola, Francesca Sparano, Maria Lucia Iacovino, Anna Castrichino, Francesca Doria, Antonello Sica, Floriana Morgillo, Giuseppe Colella, Giampaolo Tartaro, Salvatore Cappabianca, Domenico Testa, Gaetano Motta & Fortunato Ciardiello. (2021) Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. Therapeutic Advances in Medical Oncology 13, pages 175883592094941.
Crossref
Paul BrearDarby Ball, Katherine StottSheena D’Arcy & Marko Hyvönen. (2020) Proposed Allosteric Inhibitors Bind to the ATP Site of CK2α. Journal of Medicinal Chemistry 63:21, pages 12786-12798.
Crossref
Xiaoyun Lu, Jeff B. Smaill & Ke Ding. (2020) New Promise and Opportunities for Allosteric Kinase Inhibitors. Angewandte Chemie International Edition 59:33, pages 13764-13776.
Crossref
Xiaoyun Lu, Jeff B. Smaill & Ke Ding. (2020) Allosterische Kinaseinhibitoren – Erwartungen und Chancen. Angewandte Chemie 132:33, pages 13868-13881.
Crossref
Ramon MartinezIIIIII, Amy Defnet & Paul Shapiro. 2020. Next Generation Kinase Inhibitors. Next Generation Kinase Inhibitors 29 59 .
D. Samuel Metibemu, O. Adeboye Akinloye, A. Jamiu Akamo, D. Ajiboye Ojo, O. Tolulope Okeowo & I. Olaposi Omotuyi. (2019) Exploring receptor tyrosine kinases-inhibitors in Cancer treatments. Egyptian Journal of Medical Human Genetics 20:1.
Crossref
Tahia K. Mohamed, Rasha Z. Batran, Samia A. Elseginy, Mamdouh M. Ali & Abeer E. Mahmoud. (2019) Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis. Bioorganic Chemistry 85, pages 253-273.
Crossref
Lindy Astl, Amanda Tse & Gennady M. Verkhivker. 2019. Protein Allostery in Drug Discovery. Protein Allostery in Drug Discovery 187 223 .
Peng Wu & Amit Choudhary. 2018. Successful Drug Discovery. Successful Drug Discovery 65 93 .
Yilin Meng, Cen Gao, David K. Clawson, Shane Atwell, Marijane Russell, Michal Vieth & Benoît Roux. (2018) Predicting the Conformational Variability of Abl Tyrosine Kinase using Molecular Dynamics Simulations and Markov State Models. Journal of Chemical Theory and Computation 14:5, pages 2721-2732.
Crossref
José M Granadino-Roldán, Andrés Garzón, Patricia Gomez-Gutierrez, Ignacio Pasamontes-Funez, Maria Santos Tomas & Jaime Rubio-Martinez. (2018) A multistep docking and scoring protocol for congeneric series: Implementation on kinase DFG-out type II inhibitors. Future Medicinal Chemistry 10:3, pages 297-318.
Crossref
Ping-Pin Zheng, Jin Li & Johan M Kros. (2018) Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights. Medicinal Research Reviews 38:1, pages 325-376.
Crossref
Maocai Yan, Huiyun Wang, Qibao Wang, Zhen Zhang & Chunyan Zhang. (2016) Allosteric inhibition of c-Met kinase in sub-microsecond molecular dynamics simulations induced by its inhibitor, tivantinib. Physical Chemistry Chemical Physics 18:15, pages 10367-10374.
Crossref
Sun Hongmao. 2016. A Practical Guide to Rational Drug Design. A Practical Guide to Rational Drug Design 61 108 .
Peng Wu, Mads H. Clausen & Thomas E. Nielsen. (2015) Allosteric small-molecule kinase inhibitors. Pharmacology & Therapeutics 156, pages 59-68.
Crossref
Nicole C. Goodwin, Giovanni Cianchetta, Hugh A. Burgoon, Jason Healy, Ross Mabon, Eric D. Strobel, Jason Allen, Shuli Wang, Brian D. Hamman & David B. Rawlins. (2014) Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation. ACS Medicinal Chemistry Letters 6:1, pages 53-57.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.